| Literature DB >> 29764886 |
Mitsumasa Umesawa1, Mikako Hara2, Toshimi Sairenchi1, Yasuo Haruyama1, Masanori Nagao1, Munehiro Matsushita1, Gen Kobashi1.
Abstract
OBJECTIVE: Prevention of hearing impairment is important because it is difficult to recover from it. Epidemiological studies have examined the risk factors for hearing impairment; however, the association between dipstick proteinuria and hearing impairment has not been previously examined. This study aimed to clarify the association between dipstick proteinuria and hearing impairment.Entities:
Keywords: cross-sectional study; epidemiology; hearing impairment; proteinuria
Mesh:
Year: 2018 PMID: 29764886 PMCID: PMC5961557 DOI: 10.1136/bmjopen-2017-021427
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Age-adjusted and sex-adjusted characteristics of subjects according to degree of proteinuria
| Degree of proteinuria | P for ANOVA/ | ||||||||
| (−) (N=5103) | (±) (N=851) | (+) (N=198) | (≥2+) (N=34) | ||||||
| n | Mean±SE | n | Mean±SE | n | Mean±SE | n | Mean±SE | ||
| Age (years) | 45.0±0.1 | 44.3±0.3 | 45.0±0.7 | 50.9±1.6 | <0.01 | ||||
| Men (%) | 88.1 | 89.1 | 88.4 | 100.0 | 0.16 | ||||
| Body mass index (kg/m2) | 5093 | 23.4±0.0 | 847 | 23.4±0.1 | 198 | 24.3±0.2 | 34 | 24.9±0.6 | <0.01 |
| Systolic blood pressure (mm Hg) | 5103 | 116.7±0.2 | 851 | 116.4±0.5 | 198 | 117.8±1.0 | 34 | 124.1±2.3 | <0.01 |
| Diastolic blood pressure (mm Hg) | 5103 | 72.8±0.1 | 851 | 73.2±0.4 | 198 | 74.6±0.7 | 34 | 78.5±1.8 | <0.01 |
| Medication for hypertension (%) | 5103 | 9.4 | 850 | 10.5 | 198 | 19.1 | 33 | 39.7 | <0.01 |
| HbA1c (NGSP) (%) | 5101 | 5.5±0.0 | 849 | 5.6±0.0 | 197 | 5.7±0.0 | 34 | 6.0±0.1 | <0.01 |
| Medication for diabetes mellitus (%) | 5102 | 3.2 | 849 | 3.3 | 198 | 9.1 | 33 | 22.5 | <0.01 |
| Creatinine (mg/dL) | 5101 | 0.8±0.0 | 850 | 0.8±0.0 | 197 | 0.8±0.0 | 34 | 1.5±0.0 | <0.01 |
| Current smoker (%) | 5095 | 70.1 | 849 | 68.5 | 197 | 69.4 | 33 | 65.6 | 0.72 |
| Urine glucose 1+ or more (%) | 5103 | 1.7 | 851 | 2.1 | 198 | 5.0 | 34 | 8.0 | <0.01 |
| Working in a noisy place between 2008 and 2016 (%) | 5103 | 11.3 | 851 | 20.9 | 198 | 11.7 | 34 | 9.4 | <0.01 |
| Patients with hearing impairment at 1 kHz | 5103 | 88 | 851 | 11 | 198 | 5 | 34 | 3 | – |
| Patients with hearing impairment at 4 kHz | 5103 | 227 | 851 | 31 | 198 | 11 | 34 | 8 | – |
| Patients with hearing impairment at 1 kHz and/or 4 kHz | 5103 | 262 | 851 | 38 | 198 | 14 | 34 | 9 | – |
ANCOVA, analysis of covariance; ANOVA, analysis of variance; HbA1c, haemoglobin A1c; NGSP, National Glycohemoglobin Standardization Program.
Relationships between degree of proteinuria and hearing impairment
| Prevalence of hearing impairment (%) | ||||
| Age-adjusted, sex-adjusted | Multivariable-adjusted* | |||
| Case/N | Prevalence (%) | Case/N | Prevalence (%) | |
| 30 dB < in 1 kHz and/or 40 dB < in 4 kHz (overall moderate hearing impairment) | ||||
| Proteinuria | ||||
| − | 262/5103 | 5.1 | 262/5090 | 5.2 |
| ± | 38/851 | 4.7 | 38/844 | 4.6 |
| + | 14/198 | 7.0 | 14/197 | 6.8 |
| ≥2+ | 9/34 | 23.7 | 9/33 | 23.5 |
| P for ANCOVA | <0.01 | <0.01 | ||
| 30 dB < in 1 kHz | ||||
| Proteinuria | ||||
| − | 88/5103 | 1.7 | 88/5090 | 1.7 |
| ± | 11/851 | 1.4 | 11/844 | 1.4 |
| + | 5/198 | 2.5 | 5/197 | 2.5 |
| ≥2+ | 3/34 | 8.1 | 3/33 | 8.2 |
| P for ANCOVA | 0.02 | 0.03 | ||
| 40 dB < in 4 kHz | ||||
| Proteinuria | ||||
| − | 227/5103 | 4.4 | 227/5090 | 4.5 |
| ± | 31/851 | 3.8 | 31/844 | 3.7 |
| + | 11/198 | 5.5 | 11/197 | 5.4 |
| ≥2+ | 8/34 | 21.1 | 8/33 | 21.1 |
| P for ANCOVA | <0.01 | <0.01 | ||
*Adjusted for age, sex, body mass index (kg/m2), hypertension (yes or no), diabetes mellitus (yes or no), serum creatinine (sex-specific quintile) and history of noisy work environment between 2008 and 2016 (yes or no) for calculation of multivariable-adjusted prevalence of hearing impairment.
ANCOVA, analysis of covariance.
Associations between degree of proteinuria and hearing impairment according to the number of ears
| Overall hearing impairment | ||||
| Age-adjusted, sex-adjusted | Multivariable-adjusted* | |||
| Case/N | Prevalence (%) | Case/N | Prevalence (%) | |
| In one ear | ||||
| Proteinuria | ||||
| – | 176/5103 | 3.4 | 176/5090 | 3.5 |
| ± | 25/851 | 3.0 | 25/844 | 3.0 |
| + | 10/198 | 5.0 | 10/197 | 4.9 |
| ≥2+ | 7/34 | 18.9 | 7/33 | 18.9 |
| P for ANCOVA | <0.01 | <0.01 | ||
| In two ears | ||||
| Proteinuria | ||||
| – | 86/5103 | 1.7 | 86/5090 | 1.7 |
| ± | 13/851 | 1.6 | 13/844 | 1.6 |
| + | 4/198 | 2.0 | 4/197 | 1.9 |
| ≥2+ | 2/34 | 4.8 | 2/33 | 4.6 |
| P for ANCOVA | 0.54 | 0.62 | ||
*Adjusted for age, sex, body mass index (kg/m2), hypertension (yes or no), diabetes mellitus (yes or no), serum creatinine (sex-specific quintile) and history of noisy work environment between 2008 and 2016 (yes or no) for calculation of multivariable-adjusted prevalence of hearing impairment.
ANCOVA, analysis of covariance.